06-05-2025
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference
Avalyn Pharma Inc.
Topline Results from the AP02 (Inhaled Nintedanib) Phase 1 Clinical Trials Among the Company's Five Poster Presentations
4.5 Year Long-Term Safety and Efficacy Data Supporting AP01 (Inhaled Pirfenidone) from the ATLAS Open-Label Extension Trial to be Presented
Avalyn to be featured in ATS Industry Theater Program
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced multiple presentations at the American Thoracic Society (ATS) 2025 International Conference being held May 16-21, 2025, at the Moscone Center in San Francisco, CA.
'We're proud to showcase a strong portfolio of presentations at the upcoming ATS conference, which reflects the dedication of our team and collaboration with physicians and medical professionals to meet the urgent therapeutic needs in the pulmonary fibrosis community,' said Lyn Baranowski, CEO of Avalyn Pharma. 'We look forward to reporting topline data from two Phase 1 clinical trials of AP02, which support its advancement into a Phase 2 trial, and up to 240 weeks of long-term clinical efficacy and safety data on AP01. Our presence at ATS will showcase our belief that we are well-positioned to transform how pulmonary fibrosis will be treated in the future through the advent of optimized inhaled formulations that offer improved safety, efficacy and long-term adherence – a critical must-have given the progressive, chronic nature of this disease.'
Avalyn's presentations will include topline data from the single- and multiple-ascending dose Phase 1 clinical trials of AP02 (inhaled nintedanib) in healthy adult volunteers and patients with idiopathic pulmonary fibrosis (IPF) and new long-term safety and efficacy data from the ATLAS open-label extension trial of AP01 (inhaled pirfenidone) in patients with IPF and progressive pulmonary fibrosis (PPF). Furthermore, the company, in collaboration with Qureight, will present results from two deep learning-based analyses of high-resolution computed tomography (HRCT) scans and patient data from the Phase 1b ATLAS trial of AP01, exploring the utility of novel imaging biomarkers and synthetic study arms in validating treatment efficacy in patients with IPF.
Avalyn will also be featured in the ATS Industry Theater program, where Joyce Lee, M.D., Professor of Medicine in Pulmonary Sciences and Critical Care Medicine, Director of the Interstitial Lung Disease Program, University of Colorado School of Medicine, an investigator in the Phase 2b clinical trial of AP01, and a steering committee member for AP02, will provide data highlights from the Phase 1 clinical trials of AP02.
